T2期非小细胞肺癌的跨叶侵犯对T分期及其预后的影响探讨

T-stage of T2 non-small cell lung cancer with directly invasion of the adjacent lobe and its effect on prognosis

目的:探讨T2期非小细胞肺癌的跨叶侵犯对T分期及其预后的影响。方法:回顾性的收集2012年10月至2015年10月于我科住院诊治的38例T2期直接跨叶的非小细胞肺癌(T2N0M0)患者作为研究对象(跨叶T2组)。同时按1∶1比例匹配选择局限性(T2N0M0和T3N0M0)单叶肺癌患者作为对照组(局限T2组和局限T3组)。采用Kaplan-Meier生存分析法分析各组生存率并进行比较。结果:局限T2组患者5年生存率为64.2%,中位生存时间为64个月;局限T3组患者5年生存率为39.8%,中位生存时间为34个月;跨叶T2组患者5年生存率为42.1%,中位生存时间为38个月;局限T2组的生存率显著优于局限T3组(P=0.005)和跨叶T2组(P=0.007),而局限T3组和跨叶T2组之间差异无统计学意义(P=0.914)。结论:跨叶侵犯T2N0M0期非小细胞肺癌患者其T分期应进行适当的升期或修正,这一分期对于预后的评估有显著的指导意义。

Objective:To explore the T-stage of non-small cell lung cancer with directly invasion of the adjacent lobe and its effect on prognosis.Methods:38 patients with non-small cell lung cancer with directly invasion of the adjacent lobe(T2N0M0) who were hospitalized in this department from October 2012 to October 2015 were selected as the research subjects(invasion T2 group).At the same time,the patients with localized single leaf lung cancer(T2N0M0 and T3N0M0)were selected as the control group(localized T2 group and localized T3 group) according to the proportion of 1∶1.Kaplan-Meier survival analysis was used to analyze the survival rates of each group.Results:The 5 years survival rate and median survival time in localized T2 group were 64.2% and 64 months.The 5 years survival rate and median survival time in localized T3 group were 39.8% and 34 months.The 5 years survival rate and median survival time in invasion T2 group were 42.1% and 38 months.The survival rate in localized T2 group were higher than those in invasion T2 group(P=0.007) and localized T3 group(P=0.005),and the differences were statistically significant.There were no statistically significant differences in survival rate between invasion T2 group and localized T3 group(P=0.914).Conclusion:The T staging of T2N0M0 stage non small cell lung cancer with directly invasion of the adjacent lobe should be properly raised or corrected,in which had significant guiding significance for the evaluation of the prognosis.